This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
By Kalie E. Richardson — Early on March 29, 2023, FDA announced the landmark approval of Narcan (naloxone hydrochloride) Nasal Spray for use as a nonprescription opioid overdose reversal agent. I previously blogged on the February 15, 2023 Joint Meeting of the Nonprescription Drugs Advisory Committee (NDAC) and the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) which unanimously agreed that the benefit-risk profile of Narcan Nasal Spray (NNS) is “supportive of its use as a n
In this study, 255 drug targets of metformin were obtained from the BATMAN, Drugbank, PharmMapper, SwissTargetPrediction, and TargetNet databases. Meanwhile, 10,463 differentially expressed genes (DEGs) in OC were screened from GSE29450, GSE10971, GSE18520, GSE14407, and TCGA + GTEx datasets. A total of 95 common targets were obtained by deintersection of drug targets of metformin and DEGs in OC.
The annual Kidney Action Week is a virtual event put on by the American Kidney Fund designed to bring the entire kidney health community together for a week of amazing and informative content on all things related to kidney health. The event is filled with discussions, Q&As, webinars, and more — and this year, Antidote was thrilled to be involved!
This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Discount Cards, Cost-Plus Pharmacies, and PBMs: Trends, Controversies, and Outlook. Click here to see the original post and comments from January 2023. For 2023, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)—have again increased the number of drugs they exclude from their standard formularies.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
This chart shows the pharmaceutical companies with the most patents in Ukraine. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is… The post Which pharmaceutical companies have the most drug patents in Ukraine? appeared first on DrugPatentWatch - Make Better Decisions.
By Larry K. Houck — Perhaps you obtain controlled substance quotas or submit ARCOS reports? Maybe you identify and report suspicious orders or thefts/losses. Or you obtain import or export permits, submit import or export declarations or listed chemical DEA-486s. Do you want to learn more? You have your chance. DEA’s Diversion Control Division is hosting a Supply Chain Conference for registered manufacturers, distributors, importers and exporters on controlled substance and listed chemical r
Signup to get articles personalized to your interests!
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
By Larry K. Houck — Perhaps you obtain controlled substance quotas or submit ARCOS reports? Maybe you identify and report suspicious orders or thefts/losses. Or you obtain import or export permits, submit import or export declarations or listed chemical DEA-486s. Do you want to learn more? You have your chance. DEA’s Diversion Control Division is hosting a Supply Chain Conference for registered manufacturers, distributors, importers and exporters on controlled substance and listed chemical r
Each year in March, the National Institute of Diabetes and Digestive and Kidney Diseases puts on National Kidney Month , a month dedicated to raising awareness about kidney health and conditions. Chronic kidney disease, a grouping of conditions that damage the kidneys , impacts around 37 million Americans, and millions of others are considered to be at an increased risk.
This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Discount Cards, Cost-Plus Pharmacies, and PBMs: Trends, Controversies, and Outlook. Friday's webinar will include my latest thoughts on a key trend discussed in todays rerun: how plan sponsors are incorporating patient-paid prescriptions—cash-pay prescriptions and discount cards—within pharmacy benefits.
This chart shows the patent expirations for cream dosed drugs over the next decade. The term of drug patents varies. The basic term for a patent is 20 years from… The post Cream dosed drug patent expirations by year appeared first on DrugPatentWatch - Make Better Decisions.
As Women’s History Month comes to a close, I wanted to share some of the events and takeaways we learned on behalf of the BenchShe+ leadership team. We had the honor of putting together programming not just for members of the BenchShe+ employee resource group (ERG), but also hosting events company-wide to help educate and inspire our team throughout the month.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
The use of engineered genetic materials in clinical trials is rapidly expanding, with potential applications for genetic vaccines, gene-modified cellular therapies, and gene therapies. This trend came to the forefront during the COVID-19 pandemic, as the three most popular vaccines developed in response to the coronavirus contained engineered genetic materials in the form of mRNA or a genetically engineered virus.
This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Discount Cards, Cost-Plus Pharmacies, and PBMs: Trends, Controversies, and Outlook. One follow-up to this rerun: Kroger’s participation as a preferred pharmacy declined significantly due to its Express Scripts relationship. Based on early 2023 enrollment data, Kroger is preferred in plans that enrolled only 11.8 million people—a decline of 33% from the 2022 figure.
This chart shows the pharmaceutical companies with the most capsule dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most capsule dosed drugs… The post Which pharmaceutical companies have the most capsule dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
In a time with lots of hype surrounding decentralized clinical trial (DCT) solutions, let's not lose sight of the importance of a dependable and secure electronic data capture (EDC) system. This blog post walks you through the basics to keep in mind when selecting an EDC platform for your studies. The post Electronic Data Capture – The Basics appeared first on Crucial Data Solutions.
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
In “The Last of Us,” a video game and recently-wrapped HBO series , giant mutant fungi turn much of humanity into zombies. In real life, another fungus, the yeast Candida auris , is spreading, just as COVID finally fades. Candida auris is the first multi-drug resistant fungus identified. It is deadlier than familiar relative Candida albicans , which lies behind common vaginal and throat infections.
This week, I’m rerunning some popular posts while I prepare for today’s live video webinar: Discount Cards, Cost-Plus Pharmacies, and PBMs: Trends, Controversies, and Outlook. Click here to see the original post and comments from January 2023. Time for the Drug Channels annual reality check on drug pricing. The data once again tell a different story than you might read in your favorite politician’s Twitter feed or misleading news reports.
Annual Drug Patent Expirations for VANCOMYCIN Vancomycin is a drug marketed by Xellia Pharms Aps, Akorn, Fresenius Kabi Usa, Lupin Ltd, Orient Pharma Co Ltd, Strides Pharma, Watson Labs, Alkem… The post New patent for Xellia Pharms drug VANCOMYCIN appeared first on DrugPatentWatch - Make Better Decisions.
Listen on In this episode, Marie-Josee Toutounji, Medical affairs professional with over 20 years of experience in the pharmaceutical industry, discusses the pressing issue of unapproved content in the medical and regulatory field. The episode covers the potential risks of using unapproved content and tools in healthcare. Marie-Josee explores the challenges of implementing a continuous learning culture in the industry, with a focus on stakeholder engagement, compliance, and documentation to deve
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
With all of the critical data that needs to be collected over the course of a clinical trial, one might assume that all of this data must be collected and managed electronically. Yet, this is not the case. While most clinical researchers have embraced the use of specialized software platforms to help stay on top of study data, there are still some who continue to collect, store, access and analyze data using old-school pen and paper or with software (like spreadsheets) that are not fit for purpo
This week, I’m rerunning some popular posts while I prepare for tomorrow’s live video webinar: Discount Cards, Cost-Plus Pharmacies, and PBMs: Trends, Controversies, and Outlook. So far, it appears that PBMs are neither preferring Amgen's Humira biosimilar nor embracing the low-list/low-rebate version. In February, AbbVie stated that U.S. Humira sales would be decline by about 37% in 2023—which is at the lower end of its previous erosion projection of 35% to 55%.
This chart shows the drugs with the most patents in Japan. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.… The post Which pharmaceutical drugs have the most drug patents in Japan? appeared first on DrugPatentWatch - Make Better Decisions.
Predictive Oncology announces it is partnering with Integra Therapeutics, a company focused on engineering the next generation of gene writing tools to cure diseases. The collaboration was created to pursue a novel method to enhance Integra Therapeutics’ ability to use gene editing for future cancer therapies. Read about the news here. The post Predictive Oncology announces collaboration to advance gene therapy appeared first on Predictive Oncology.
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
You’re reading Codon, a newsletter about biology, technology, and the future. View our database of DARPA neurotechnology projects online. “I am a brain, Watson. The rest of me is a mere appendix.” — Arthur Conan Doyle Ted Berger was running out of money. In 2009, the USC professor received millions from the Defense Advanced Research Projects Agency, or DARPA, to build a device that plugs into the brain and enhances memory recall.
The United States devotes roughly $200 billion to national health expenditures on medical devices every year. In fact, the global medical devices market is projected to grow from $495.46 billion in 2022 to $718.92 billion by 2029. Medical device companies historically have operated under the assumption that if they built it, physicians would buy it.
Annual Drug Patent Expirations for ISENTRESS Isentress is a drug marketed by Msd Sub Merck and is included in three NDAs. It is available from eight suppliers. There are six… The post New patent for Msd Sub drug ISENTRESS appeared first on DrugPatentWatch - Make Better Decisions.
The drug warning information in ChEMBL has been updated for version 32. In particular, the withdrawn drug data has been fully reviewed and, to assist the manual curation process, our rules have been updated, clarified and formally written. In ChEMBL, a withdrawn drug is an approved drug (ie Phase 4) that has subsequently been withdrawn for toxicity reasons.
The Food and Drug Administration’s (FDA’s) proposed single institutional review board (sIRB) mandates are in part designed to support greater efficiencies and consistencies when conducting multisite research. This change has the potential for a substantial impact on sponsors and contract research organizations (CROs), as well as institutions conducting multisite research.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
105 
Let's personalize your content